Cooley, Sarah Anne2010-03-252010-03-252009-11https://hdl.handle.net/11299/59769University of Minnesota M.S. thesis. November 2009. Major: Clinical Research. Advisors: Jeffrey S Miller, MD, Daniel J Weisdorf, MD, Chap T Le, PhD. 1 computer file (PDF); iv, 36 pages, appendix 29-36.Survival after unrelated donor (URD) hematopoietic cell transplantation (HCT) for Acute Myeloid Leukemia (AML) is limited by toxicity and relapse. Killer-cell immunoglobulin-like receptors (KIR) control NK cell alloreactivity after HCT. Hypothesizing that donor KIR genotype (A/A: 2 A KIR haplotypes; B/x: ≥ 1 B haplotype) would affect outcomes, we genotyped donors and recipients from 448 URD transplantations for AML. Three year overall survival was significantly higher after transplantation from a KIR B/x donor (31% [95% CI: 26-36] vs. 20% [95% CI: 13-27]; p = 0.007). Multivariate analysis demonstrated a 30% better relative risk of relapse-free survival with B/x vs. A/A donors (RR 0.70 [95% CI 0.55-0.88]; p=.002). B/x donors were associated with more chronic GVHD (RR 1.51 [95% CI 1.01-2.18]; p=.03), but not more acute GVHD, relapse or treatment-related mortality. This analysis demonstrates that HCT from unrelated donors with KIR B haplotypes confers significant survival benefit for patients with AML.en-USUnrelated donor (URD)Acute Myeloid Leukemia (AML)Immunoglobulin-like receptorsToxicityClinical ResearchThesis or Dissertation